TheraRadar
Clinical-Stage Companies / Shin Poong Pharmaceutical

Shin Poong Pharmaceutical

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 2/14/2025

20
Total Trials
5
Phase 3
9
Phase 2
3
Recruiting
162
Score

Pipeline by Phase

Phase 3
5
Phase 2
9
Phase 1
5

Therapeutic Focus

Ischemic Stroke COVID-19 Essential Hypertension Hypertension (HTN) NYHA Class III Heart Failure

Clinical Trials (20)

NCT06660719 Phase 3 RECRUITING

Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care

Started: 2/14/2025

NCT06399042 Phase 3 ACTIVE NOT RECRUITING

Pivotal Study to Evaluate Efficacy and Safety of SP5M002 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis

Started: 6/14/2023

NCT06307847 Phase 3 COMPLETED

Pivotal Study to Evaluate Efficacy and Safety of SP5M001 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis

Started: 4/14/2021

NCT05084911 Phase 3 COMPLETED

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)

Started: 10/18/2021

NCT03288038 Phase 3 COMPLETED

The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia

Started: 10/13/2014

NCT06826872 Phase 2 RECRUITING

Efficacy and Safety of SPC1001 in Patients With Essential Hypertension

Started: 6/12/2024

NCT04532931 Phase 2 COMPLETED

Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

Started: 9/3/2020

NCT07064525 Phase 2 ENROLLING BY INVITATION

Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension

Started: 12/5/2024

NCT06212648 Phase 2 COMPLETED

Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

Started: 3/25/2022

NCT04479449 Phase 2 COMPLETED

Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA

Started: 3/18/2019

NCT05633420 Phase 2 COMPLETED

Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

Started: 7/24/2022

NCT04475107 Phase 2 COMPLETED

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

Started: 7/9/2020

NCT02787278 Phase 2 COMPLETED

Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA

Started: 6/5/2016

NCT02944734 Phase 2 COMPLETED

Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

Started: 9/1/2014

NCT06225635 Phase 1 COMPLETED

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab

Started: 1/1/2022

NCT05574166 Phase 1 TERMINATED

A Phase I Study to Evaluate Safety and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8356

Started: 1/3/2021

NCT04770194 Phase 1 COMPLETED

Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SP-8008

Started: 10/1/2019

NCT01757795 Phase 1 COMPLETED

Safety, Tolerability and Pharmacokinetics of SP-8203

Started: 12/23/2013

NCT01926652 Phase 1 COMPLETED

Safety and Pharmacokinetics Study of Amlodipine 10mg and Candesartan 32mg

Started: 7/1/2013

NCT03201770 Phase 4 COMPLETED

Cohort Event Monitoring Study of Pyramax®

Started: 6/22/2017

Drug Candidates

Paracetamol Artesunate-amodiaquine Pyronaridine-artesunate Favipiravir plus Nitazoxanide Sofosbuvir/daclatasvir SPC1001 Low SPC5002 SPC5003 SPC5004 SP-8203
Activity Status: Slowing
Last Trial Started: 2/14/2025
Last Trial Ended: 3/24/2023
Trials (12 months): 0
Completed Trials: 15
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.